Overview

A 6-month Randomised, Double-blind, Open Arm Comparator, Phase IIb, With AZD9056, in Patients With Rheumatoid Arthritis (RA)

Status:
Completed

Trial end date:
2009-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to confirm that AZD9056 is effective in treating rheumatoid arthritis with regard to signs and symptoms and to determine what dose is favourable over a 6-month treatment period. Patients will receive background treatment with either Methotrexate or Sulphasalazine

Phase:

Phase 2

Details

Lead Sponsor:

AstraZeneca

Treatments:

Etanercept